Table 2

Efficacy results of candidate vaccines for active immunization against respiratory syncytial virus

Class

Vaccine structure

Clinical trial phase

Results


Live attenuated[74]

rA2cp248/404ΔNS2

rA2cp530/1009 Δ NS2

I

- Not infectious in adults

- Well tolerated, no symptomatic illness

- Infected 50% and 20% sero-negative infants respectively at a dose of 105 pfu

Live attenuated[24]

rA2cpts248/404/1030/ Δ SH

I

- only candidate with a demonstrated safety profile

- 44% vaccinated infants had detectable antibodies after 2 doses of 5.3log10 pfu

b/hPIV3/RSVF2[44]

Recombinant attenuated para-influenza virus type-3 expressing RSV-F protein

I

- tested in 120 1-9 year old sero-positive children.

- acceptable safety profile

- minimally immunogenic

Subunit[32,75,76]

Purified F Protein - PFP 1 and PFP 2

Discontinued after phase I/ II

- Pilot study shows significant antibody titres in children with CF

- Safe and immunogenic in 12-48 month old sero-positive children

Subunit[75,76]

PFP 3

Discontinued after phase II

- Double blinded controlled multi-centre study in CF children

- Safe and immunogenic but no reduction in LRTI

Subunit[75,76]

BBG2Na

Animal models

- Safe and immunogenic in adult mice.

- Phase III trials in adult volunteers stopped due to unexpected adverse effects24


Nair et al. BMC Public Health 2011 11(Suppl 3):S30   doi:10.1186/1471-2458-11-S3-S30

Open Data